Pages
- Dichotomy in Regioselectivity of SnAr Reactions with 2-MeSO2-4-Chloropyrimidine
- Correlating Activation Energy with Relevant Orbital Energy
- Dichotomy in Regioselectivity of Electrophilic Reaction of 3-Acetyl-5-hydroxylindole
- Quantum Mechanics Quiz part II
- Unusual Reactivities of Polyhalogenated Heteroaromatic Substrates are Predictable
- A QM Study of the Hydroaminomethylation of Olefins
- Quantum Mechanics Quiz
- Visualizing Hydrogen Bonds using Electron Density Maps
- QM-ML tool for Deoxyfluorination
- QM Torsion Scan for Analysis of Atropisomers
- PDF Redirect
- Frequently Asked Questions
- Is SN2 Substitution at sp2 Reaction Centers Feasible ?
- Intriguing Observations with Snar Reaction of 4-Nitrobenzonitrile
- Highly Regioselective Snar of a Polyhalogenated Benzaldehyde
- QM Analyses of Regioselectivity in Chan-Lam Reaction
- QM Analyses for Cysteine – Chloroacetamide Bioconjugation
- One Versatile Intermediate, Under Three Different Conditions, Selectively Provides Three Different Heterocyclic Products Benzofuran Synthesis via Acid Catalyzed Cyclization of Acetal
- Benzofuran Synthesis via Acid Catalyzed Cyclization of Acetal
- Unraveling Divergence in Haloselectivity of SNAr and Cross Coupling vs Halogen-Metal Exchange Reactions
- Meeting Request – Webinars
- Thank You – Resources
- Thank You – Webinar
- Thank You – Request a Meeting
- Thank You – Newsletter Subscription
- Microscale Thermophoresis
- Graphic + Shortcode Test
- Site Map Page
- Subscribe to Our Newsletter
- QM analyses of Electrophilic Aromatic Iodination
- Understanding the highly variable Regioselectivity in SNAr reaction of Dichloropyrimidines
- Correlating Reactivity Trends with Frontier Molecular Orbitals
- Activation Energy Estimation for Alkylation of Pyrazole (Part II)
- Assessing Reactivity with LUMO and HOMO Energy Gap
- A QM Study of the Reaction Mechanism of Diazotransfer
- A QM Study of the para Regioselectivity of TBABr3 Bromination
- Exploring the Reaction Mechanism of Menke Nitration
- A Comprehensive Overview of Quantum Mechanics-Free Organic Chemistry
- Analysis of Ambident Reactivity of Dimethyl Carbonate
- Tele-Substitution of 2,3-Dichloropyrazine
- Integrating QM HOMO/LUMO/13C NMR Calculations
- Predicting Regioselectivity of Electrophilic Halogenation Reactions
- Ketalization with Tetramethoxysilane: QM Mechanism Investigation
- Alcohol Speed up Boc Protection of Primary Amines
- Application of Torsion Scan in Medicinal Chemistry
- The Mysterious Factor X that Confers Stereoselectivity
- LUMO-Assisted Design of Disulfide Linkers
- QM Assisted Structure Assignment with 13C NMR Calculation
- SNAr Reaction of Polyhalogenated Heterocycles
- Application of Electrostatic Potential Map in Acidity Estimation
- Standing on the Shoulders of Giants Hammond’s Postulate
- LUMO Analysis of Electrophiles (Part II)
- Stepwise Multiple Halogenation Coupling Reaction Strategies
- Sequential Cross Coupling Reactions of Polyhalogenated Heterocycles
- Application of Conformational Analyses & HOMO Map for Stereo-selectivity Prediction
- Application of Electrostatic Potential Map in Acidity Estimation
- Application of HOMO in Electrophilic Reactions
- Application of LUMO in Nucleophilic Reactions
- Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
- Biophysical Assays and Screening
- Resources
- Drug Discovery Services
- About WuXi Biology
- News & Events
- Resource Library
- Contact Us
- Solutions
- Phase
- Platforms
- Chemistry Discovery Platform
- Structure Based Drug Discovery
- Biology Platforms
- Drug Metabolism and Pharmacokinetics
- In Vitro Biology
- High Content Platform
- High Throughput Screening
- In Vitro Assays for Diabetes and Other Metabolic Diseases
- Cancer Cell Panel & In Vitro Oncology Assays
- Radioactive Assays
- GPCR, Transporter, NHR
- Cellular Assays
- Kinase Assay
- Ion Channel
- Enzymes/Biochemical Assays
- In vitro toxicity studies
- In vitro Safety Pharmacology Profiling
- Screening Platform
- Pharmacology Studies
- Toxicology Platform
- Biomarker Platform
- Translational Platform
- Therapeutic Areas
- Therapeutic Modalities
- Biology Services
- Gene Manipulation
- Structural Biology
- in vitro Biology
- in vivo Pharmacology
- Oncology and Immunology
- Home
- ADC
- Biotransformation Platform
- Chemistry AI
- Catalyst Screening
- Electrochemistry Platform
- Flow Chemistry
- Oligo & Conjugation
- PROTAC®
- Photoredox
- Quantum Mechanics
- Impurity Profiling
- Isotope Labeling Chemistry
- Library Design & Synthesis
- Steroids
- OLED and Polymer Supporting
- Nucleoside/tides
- Material Science
- Macrocyclic Chemistry
- Lipid Chemistry Capabilities
- Late Stage Functionalization
- Fluorine Chemistry Platform
- Fluorescent Bio-probe and Labeling Synthesis
- Discovery Process Chemistry (DPC)
- Deuteration Chemistry
- Carbohydrate Chemistry
- Boron Chemistry
- Agricultural Chemistry
- Steroids
- OLED and Polymer Supporting
- Nucleoside/tides
- Material Science
- Macrocyclic Chemistry
- Lipid Chemistry Capabilities
- Late Stage Functionalization
- Fluorine Chemistry Platform
- Fluorescent Bio-probe and Labeling Synthesis
- Discovery Process Chemistry
- Deuteration Chemistry
- Carbohydrate Chemistry
- Boron Chemistry
- Agricultural Chemistry
Posts by category
- Category: Events
- ACS Northeast Regional Meeting NERM 2023
- Proventa Drug Discovery Biology
- Proventa Medicinal Chemistry
- Proventa Drug Discovery Biology
- Proventa Medicinal Chemistry
- Discovery on Target
- 3rd RSC Anglo-Nordic Medicinal Chemistry Symposium
- BIO International
- The ELRIG therapeutic oligo and the European chemical biology conference
- AACR
- Swiss Biotech Day
- Biologics UK
- Research and Innovation
- 7th RSC-BMCS/SCI Symposium on Ion Channels as Therapeutic Targets
- BIO Europe Spring
- AMR
- Drug Discovery Chemistry
- ACE Drug Discovery Summit
- UCLA MedTech
- PepTalk
- Biotech Showcase
- JP Morgan 41st Annual Healthcare Conference
- BioSeed
- 3rd PSL Chemical Biology Symposium
- Introduction into Fragment Based Drug Discovery
- Discovery and Characterization of Oligonucleotide Therapeutics
- 5th Annual RNA-Targeted Drug Discovery Summit
- Genesis
- SMR RSC Recent trends in medicinal chemistry and enabling technologies
- BIOFIT
- Proventa Medicinal Chemistry Meeting
- 10th International Symposium On DNA-Encoded Chemical Libraries
- Proventa Drug Discovery Biology
- AASLD
- SITC
- NESACS Process Chemistry Symposium
- Webinar: Leveraging Novel Modalities for Oncology Therapies
- Webinar: Introduction to Fragment Based DD
- 10th Annual NESACS Annual Adv. In Chemical Science Symp
- 18th OTS Annual Meeting
- RNA Leaders USA Congress 2022
- XXVII EFMC International Symposium on Medicinal Chemistry
- PROTEIN SCIENCES IN DRUG DISCOVERY 2022
- CPHI
- Tides Europe 2022
- BIO Europe 2022
- Discovery on Target 2022
- Drug Discovery 2022
- NLSDays 2022
- EuroQSAR2022
- Oligonucleotide Therapeutics and Delivery
- EUROTOX – ICT 2022 XVIth International Congress of Toxicology
- Neuroscience Discovery Symposium
- Oligonucleotide Chemistry & Therapeutics Symposium
- ChemOutsourcing
- EFMC-ISMC 2022 International Symposium on Medicinal Chemistry
- Aging research and drug discovery meeting
- 36th European and 12th International Peptide Symposium
- BIO International Convention
- Discovery Europe 2022
- Medicinal Chemistry- Strategy Meeting Europe 2022
- Drug Discovery Biology – Strategy Meeting Europe 2022
- Swiss Biotech Day 2022
- Drug Discovery Chemistry 2022
- BioTrinity 2022: Catalysing Growth in the Life Sciences Industry
- 33rd Medicinal Chemistry in Eastern England
- Category: News
- EFMC-WuXi AppTec Award for Excellence in Chemical Biology
- Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies
- A partnership to jumpstart the launch of early-stage startups with access to world-class discovery platform.
- DELFinder helps Janssen R&D team publish DEL-related article in the journal ACS Medicinal Chemistry Letters.
- WuXi AppTec HitS launches the DEL Laboratory in Munich, Germany
- WuXi AppTec Teams Up With Danish BioInnovation Institute
- Organic Letters: WuXi AppTec Developed Novel Photoredox-Mediated Decarboxylative Coupling between α‑Amino Acids and DNA-Conjugated Carbonyls
- Bioconjugate Chemistry: WuXi AppTec Developed Novel DNA-Compatible Copper-mediated Oxidative Amidation Reaction, in Collaboration with AbbVie.
- Organic Letters: WuXi AppTec Developed Novel DNA-Compatible One-Pot Click Reactions
- iScience: WuXi AppTec Together With Shanghai Institute of Materia Medica (SIMM) Developed Novel DNA-Compatible Pictet-Spengler Reaction Aided By Machine Learning Building Block Filtering
- The revamped DELFinder 2.0 is now online! No Login Required! More efficient search！More comprehensive information!
- Organic Letters: WuXi AppTec Developed Novel DNA Compatible Intermolecular Wittig Olefination
- WuXi AppTec Developed Novel Suzuki-Miyaura Coupling Strategy for DEL Synthesis
- DELFinder, A Powerful Tool For Tracking DEL Technology Available Online!
- Category: Uncategorized
Resources
- Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1α
- Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step
- Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4
- Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines
- KRAS-related Genetically Engineered Cell Lines and In Vivo Models
- WuXi Biology Fact Sheet
- Targeted Protein Degradation
- In Vitro Imaging Services
- CDK4/6 Inhibitor Resistant Breast Cancer Models
- Ligand Finding and Chemistry Workflows for Targeted Protein Degradation
- Biological Characterization and Development Workflows for Targeted Protein Degradation
- OncoWuXi Newsletter December 2022
- Discovery Newsletter Special New Year Edition 2023
- DNA-encoded chemical libraries
- Introduction into Fragment Based Drug Discovery
- Drugging the Undruggable: Leveraging the Right Screening Methods for Challenging Targets
- WuXi AppTec in vitro Neuroscience Services
- OncoWuXi Newsletter November 2022
- Discovery Newsletter November 2022
- How Does It Work? | CRISPR Mechanism
- How Does It Work? | Protein Based Vaccines
- How Does It Work? | Adenovirus Vaccines
- How Does It Work? | mRNA Vaccines
- How Does It Work? | Peptide-Oligonucleotide Conjugates
- How Does It Work? | Aptamers
- How Does It Work? | Individualized Oligonucleotide Therapies
- How Does It Work? | Antibody Drug Conjugates
- How Does It Work? | Antisense Oligonucleotide Therapy
- How Does It Work? | Peptibodies
- PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System
- Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
- WuXi AppTec Oligonucleotide Biology Platform
- How Does It Work? | Targeted Protein Degrader
- How Does It Work? | RNAi
- Oligonucleotide Drug Development (CMC)
- Oligonucleotide Drug Discovery
- Pain Discovery Assays & in vivo Studies
- OncoWuXi Newsletter: June 2022
- WuXi AppTec Discovery Services
- Bone metastasis platform to evaluate prophylaxis and treatment
- Quality Control for DNA-Encoded One-Bead-One-Compound (OBOC) Libraries
- Discovery of RNA Targeting Small Molecule Using DNA-Encoded Library Technology
- Integrating Practical Machine Learning and Quantum Mechanics Tools to Synthesis in Medicinal Chemistry
- Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
- Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability
- HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES
- RARE DISEASES: OPPORTUNITIES AND CHALLENGES FOR TREATMENTS DELIVERED BY ADENO-ASSOCIATED VIRUSES
- Optimizing Drug Pipelines With Biophysical Methods
- Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren’s syndrome model in mice
- Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer
- Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs
- Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies
- Developing a panel of orthotopic syngeneic tumor models for IO drug discovery
- Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery
- Mouse hind limb tumor metastatic model to evaluate prophylaxis and treatment
- Establishment of spatial transcriptomics assay to find the mechanism of immune therapy against tumors
- Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response
- Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
- Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies
- Evaluation of the efficacy of ADC in vitro and in vivo
- The critical platforms of PROTAC validation
- Structure determination: comparison of methods
- WuXi Discovery Services Newsletter: November 2021
- WuXi Discovery Services Newsletter: October 2021
- WuXi Discovery Services Newsletter: June 2021
- WuXi Discovery Services Newsletter: April 2021
- WuXi Discovery Services Newsletter: March 2021
- WuXi Discovery Services Newsletter: February 2021
- WuXi Biology GPCR Cell Lines and Assays
- Early in vitro safety panel - Assays and Data Summary
- One-Stop Target-to-Hit Solutions
- DELpro: A New Method of Hit Discovery
- CRISPR Library Screen to Identify Driver Mutations of Tumor Growth and Metastasis
- Self Service DNA Encoded Library Screening
- Target to Hit Finding: New Methods in Fragment-Based Drug Discovery
- How to Accelerate the Rate Limiting Step in Drug Discovery, Synthesis of Target Molecules
- DNA-Encoded Libraries in Drug Discovery - Advances in Screening and Chemistry
- Enable Pharma and Biotech Innovation through Open-Access Platform
- Fragment Screening and Biophysical Hit Validation at WuXi AppTec’s HitS
- Immuno-Oncology Platform to Enable Discovery from Target to Drug
- Enabling Technologies for Targeted Protein Degradation Webinar
- NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis
- Introduction to Self-Service DNA-Encoded libraries (DELs)
- New Platform from Target-to-Hit
- Enable Pharma and Biotech Innovation through an Open-access Platform
- Enabling Technologies For Bifunctional Molecule Discovery And Characterization
- AAV Based Gene Therapy for Rare Genetic Disorders: Strategies and Challenges
- Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
- Novel Peptide Hit Identification and Lead Generating Strategies for Drug Discovery
- Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research
- Enabling Drug Discovery with Diverse Lead Generation Platforms
- Optimizing Drug Discovery Pipelines with Biophysical Methods
- The Evolving Role of Mass Spectrometry in Drug Discovery
- Discovery of RNA binding molecule using DNA-encoded library technology
- Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets
- Quantitative Histopathology of Fibrosis in an Animal Model of NASH
- Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
- Validation of GVHD in mouse model for preclinical efficacy screen
- CRISPR library screens identify frequent cancer mutations regulating PD-1 blockade response
- Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer
- Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics
- Protein Degradation: Shifting the Paradigm of Resistance and Undruggables for Unmet Medical Needs in Cancer, Neuroscience, and Beyond
- Empowering Organic Syntheses with Quantum Mechanics Analyses
- The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia
- Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
- Faster with high-speed fragment screening — Accelerate your drug discovery campaign
- Unlocking the potential of DEL | Inspire Hit Discovery
- Enabling Technology for Targeted Protein Degradation
- Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
- CRISPR Library Screen: A Powerful Tool For Identifying Novel Tumor Targets
- Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes
- How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox
- Outsourcing Drug Discovery and Development: Considerations For Emerging Biopharma Companies
- Quantum Mechanics for Organic Chemists: An Experimentalist Approach
- Target Discovery & Validation
- CAR-T TCR-T
- Targeted Protein Degradation Platform PROTAC
- Antibody and Protein Preparation Services
- One-stop DEL services from target to hit series - DELpro
- Open Access to DEL for data sharing - DELopen
- DNA-encoded libraries for academic - DELopen Handbook
- DEL Screening - DELight Handbook
- Discovery Chemistry Outsourcing Services
- Translational Oncology
- Patient-Derived Xenograft (PDX) Tumor Models
- Immuno-Oncology Services
- CRISPR/Cas9 Gene Editing
- Cell Line-Derived Xenograft (CDX) Tumor Models
- WuXi Oncology and Immuno-Oncology Services
- Virology and Viral Vector Platforms
- WuXi AppTec in vitro Safety Pharmacology Profiling
- in vitro Toxicity Services
- HBV Discovery Services
- Clinical Virology
- Cancer Cell Panel
- Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors
- Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren's syndrome model in mice
Resource Type
- Article
- Brochure
- Case Study
- Ebook
- Infographic
- Latest Science
- Newsletter
- Poster
- Presentation
- Publication
- Video
- Webinar
- White Paper
Resource Topics
- Antibodies
- Antibody Drug Conjugate
- Autoimmune and Inflammatory Diseases
- Biochemical Assays
- Biomarkers
- Biophysical Assays
- Candidate Selection
- CAR-T Cell
- Cardiovascular & Metabolic Diseases
- Cell Therapies
- Cell-based Assays
- Cells and Protein Science
- Central Nervous System & Pain
- Chemical Biology and Proteomics
- Clinical Bioanalysis
- CRISPR/Cas9
- Dermatology
- Discovery Chemistry
- DNA-Encoded Library (DEL)
- DRUG DISCOVERY AND INNOVATION
- Fragment-Based Drug Discovery
- Gene Manipulation
- Gene Therapies
- High-throughput screening (HTS)
- Hit Finding
- Hit-to-Lead
- Immunology
- in silico services
- in vitro biology
- in vivo Pharmacology
- in vivo Toxicology
- Infectious Diseases
- Lead Optimization
- Liver Diseases
- Mass Spectrometry-based Assays
- Metabolic Diseases
- NASH
- Oligonucleotides
- Oncology
- Oncolytic Viruses
- Ophthalmology
- Phenotypic Assays
- Quantum Mechanics
- Rare Diseases
- Respiratory Diseases
- Safety and Early Toxicity
- Screening Libraries
- Screening Services
- Small Molecules
- Stages
- Structural Biology
- Target Identification and Validation
- Target-Specific Assays
- Targeted Protein Degradation
- TECHNOLOGY PLATFORMS
- THERAPEUTIC AREAS
- THERAPEUTIC MODALITIES
- Tumor Models